Evidence map›Paper›PMID 34200787›Full record

ArticleBiology2021

A Reliable and Standardizable Differential PCR and qPCR Methodology Assesses HER2 Gene Amplification in Gastric Cancer.

Ignacio Juarez, Juan Francisco Toro-Fernandez, Christian Vaquero-Yuste, Marta Molina-Alejandre, Inmaculada Lasa, Remedios Gomez, Adela Lopez, Jose Manuel Martin-Villa, Alberto Gutierrez

Open access · goldAbstract read
In one paragraph

Article in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ignacio JuarezDepartment of Immunology, Ophthalmology and ENT, Facultad de Medicina, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain.
Juan Francisco Toro-FernandezDepartment of Immunology, Ophthalmology and ENT, Facultad de Medicina, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain.
Christian Vaquero-YusteDepartment of Immunology, Ophthalmology and ENT, Facultad de Medicina, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain.
Marta Molina-AlejandreDepartment of Immunology, Ophthalmology and ENT, Facultad de Medicina, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain.
Inmaculada LasaHospital Universitario Príncipe de Asturias, 28006 Madrid, Spain.ORCID 0000-0003-0796-6230
Remedios GomezHospital Universitario Príncipe de Asturias, 28006 Madrid, Spain.
Adela LopezHospital Universitario Príncipe de Asturias, 28006 Madrid, Spain.ORCID 0000-0001-7159-043X
Jose Manuel Martin-VillaDepartment of Immunology, Ophthalmology and ENT, Facultad de Medicina, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain.ORCID 0000-0002-2436-8585
Alberto GutierrezHospital Universitario Príncipe de Asturias, 28006 Madrid, Spain.
Universidad Complutense de Madrid · ESHospital Universitario Príncipe de Asturias · ES

Funding

European Regional Development Fund PI12/01663European Regional Development Fund PI18/00626Instituto de Salud Carlos III PI12/01663Instituto de Salud Carlos III PI18/00626Real Colegio Complutense CT28/16Universidad Complutense de Madrid CT28/16
6 · The paper itself

Abstract

We have applied two PCR techniques, differential PCR (diffPCR) and qPCR for the identification of HER2 gene amplifications in genomic DNA of tumor and distal gastric samples from patients with gastric cancer. The diffPCR technique consists of the simultaneous amplification of the HER2 gene and a housekeeping gene by conventional PCR and the densitometric analysis of the bands obtained. We established a cut-off point based on the mean and standard deviation analyzing the DNA of 30 gastric tissues from patients undergoing non-cancer gastrectomy. diffPCR and qPCR yielded consistent results. HER2-overexpression was detected in 25% of patients and was further confirmed by immunohistochemistry and immunofluorescence. The approaches herein described may serve as complementary and reliable methods to assess HER2 amplification.

Indexed as

cancergastric cancerHER2immunotherapyPCR

Identifiers

PMID34200787
PMCPMC8230392
OpenAlexW3166483369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.